Abstract
Frankly, Japan is at the end of the line of current clinical theranostics such as
PRRT and PSMA. Many patients go abroad for PRRT and PSMA treatment. This
lamentable situation has been caused mainly by the strict regulations as well as the
limited number of isolation rooms available for these purposes in this country. But
despite this, Japanese scientists are developing several unique activities in theranostics,
including 211At[NaAt] for 131I radioiodine refractory thyroid cancer and meta-211Atastato-
benzyl guanidine (211At-MABG) for 131I-MIBG refractory pheochromocytoma/
paraganglioma, which are currently ready for investigator-initiated trial. There are
several other developments in this field. Such information is described in this short
article.
Keywords: 131I-MIBG, 211At[NaAt], 225Ac-fibroblast activation protein inhibitor (FAPI), 64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM), Mmeta-211At-astato-benzylguanidine (211At-MABG).
Related Books
Advances in Cancer Nanotheranostics for Experimental and Personalized Medicine
Cancer Metastasis and Cancer Stem Cell/Niche
Cancer Preventive and Therapeutic Compounds: Gift From Mother Nature
Controversies in Neuro-Oncology
Current Advances in Breast Cancer Research: A Molecular Approach
Cutting Edge Therapies for Cancer in the 21st Century
Frontiers in Cancer Immunology
Frontiers in Cancer Immunology
Frontiers in Clinical Drug Research - Anti-Cancer Agents
Frontiers in Clinical Drug Research - Anti-Cancer Agents